Carfilzomib with Lenalidomide and Low-Dose Dexamethasone or Single-Agent Carfilzomib for Patients with Multiple Myeloma


Carfilzomib with Lenalidomide and Low-Dose Dexamethasone or Single-Agent Carfilzomib for Patients with Multiple Myeloma
Slides from presentations at ASH 2011 and transcribed comments from a recent interview with Paul G Richardson, MD (1/24/12)

Jakubowiak AJ et al. Final results of a frontline Phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). Proc ASH 2011;Abstract 631.

Vij R et al. Final results from the bortezomib-naïve group of PX-171-004, a Phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. Proc ASH 2011;Abstract 813.

Dr Richardson is Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute in Boston, Massachusetts.